A retrospective, multicenter study of utilization and treatment patterns of fostamatinib in patients with Chronic Immune Thrombocytopenic Purpura
Latest Information Update: 23 Jan 2023
At a glance
- Drugs Fostamatinib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 23 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition